Technology Development

Farids Group banner

We are primarily interested in technology development with a view to generation of biologics (peptides and miniproteins) targeting dysfunctional p53 pathway components. In particular, we develop and employ a range of directed evolution methodologies for protein engineering and selection. These approaches are also being used to engineer/re-purpose enzymes for industrially relevant applications, with current focus on development of “greener” enzyme alternatives for pharmaceutical synthesis. A further area of interest is development of novel biosensing platforms, with emphasis on modular protein biosensors for facile drug screening and diagnostic applications.

Current members

Farid J. Ghadessy - Group Leader 

Siau Jia Wei 

Chee Min Qi Sharon 

Ding Ke 

Ng Aik Seng 

Barindra Sana 

Lau Sze Yi

Teresa Ho                                                             

Recent publications

  1. Development and structural characterization of an engineered multi-copper oxidase reporter of protein-protein interactions. Sana B, Chee SMQ, Wongsantichon J, Raghavan S, Robinson RC, Ghadessy FJ. J Biol Chem. 2019 Feb 15.

  2. Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function. Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP, Ghadessy FJ. Protein Eng Des Sel. 2018 Jul 1;31(7-8):301-312.

  3. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids. Chee SMQ, Wongsantichon J, Siau J, Thean D, Ferrer F, Robinson RC, Lane DP, Brown CJ, Ghadessy FJ. PLoS One. 2017 Dec 11;12(12).

  4. Development of a genetically programed vanillin-sensing bacterium for high-throughput screening of lignin-degrading enzyme libraries. Sana B, Chia KHB, Raghavan SS, Ramalingam B, Nagarajan N, Seayad J, Ghadessy FJ. Biotechnol Biofuels. 2017 Feb 3;10:32.